Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS

Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2is) are widely used in clinical practice for their demonstrated cardiorenal benefits, but multiple adverse events (AEs) have been reported. We aimed to describe the distribution of SGLT2i-related AEs in different systems and identify impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiang, Ye, Xiaofei, Guo, Xiaojing, Liu, Dongxu, Xu, Jinfang, Hu, Fangyuan, Zhai, Yinghong, Gao, Yongqing, Xu, Xiao, Dong, Ziwei, He, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721280/
https://www.ncbi.nlm.nih.gov/pubmed/34987394
http://dx.doi.org/10.3389/fphar.2021.766125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721280/
https://www.ncbi.nlm.nih.gov/pubmed/34987394
http://dx.doi.org/10.3389/fphar.2021.766125

Ejemplares similares